Alterity Therapeutics Ltd. (ATHE) Price to Earnings Ratio
Alterity Therapeutics (ATHE) automates the synthesis of Parkinson's disease medications using algorithms while ensuring physicians maintain control over patient status. The business is currently focused on completing molecule trials for the therapy of rare pathologies before onboarding partners. This price chart on GURU.Markets, where the indicator stands at -2.40, complements data regarding the company's sustainable approach to bioethics and the minimization of chemical waste.
Comprehensive metric breakdowns and analytics for Alterity Therapeutics Limited (ATHE)
- price and consensus price forecast:
- market capitalization details:
- book capitalization information:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Alterity Therapeutics|ATHE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Alterity Therapeutics Limited|ATHE - Company Total Debt|Debt to Book Capital Alterity Therapeutics Limited|ATHE - Company Long-Term Liabilities|Short-Term Debt Alterity Therapeutics|Intermediate Coverage Ratio alteritytherapeutics.com
- earnings and valuation multiples information:
ATHE - Net Income|Future Net Profit Alterity Therapeutics|ATHE - P/E Multiple|Future Price to Earnings Multiple Alterity Therapeutics|ATHE - PEG Multiple|Company Value to EBITDA Alterity Therapeutics Ltd|ATHE - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Alterity Therapeutics|ATHE - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth alteritytherapeutics.com|ATHE - Earnings per share growth in current year|Net earnings per share change forecast for next year Alterity Therapeutics
- company sales and revenue statistics:
General company analysis:Alterity Therapeutics Ltd, ATHE
Alterity Therapeutics (ATHE) focuses on developing drugs for neurodegenerative pathologies, operating on investments without stable operating income. Under these conditions, the company's historical P/E ratio reflects the relationship between market value and net income, helping to distinguish an undervalued asset from a "value trap" and avoid freezing capital in a loss-making business through an analysis of payback dynamics.
Competing companies
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
